Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 40 entries
Sorted by: Best Match Show Resources per page
Second Meeting of the French CEIP (Centres d'Évaluation et d'Information sur la Pharmacodépendance). Part I: How to Evaluate and Prevent the Abuse and Dependence on Hypnotic/Anxiolytic Drugs?.

Therapie

Micallef-Roll J, Lapeyre-Mestre M.
PMID: 27392928
Therapie. 2009 Nov-Dec;64(6):355-64. doi: 10.2515/therapie/2009054.

Les deuxièmes journées de Pharmacodépendances organisées par le réseau français des CEIP Addictovigilance (Centres d'Évaluation et d'Information sur la Pharmacodépendance) se sont tenues lors du congrès annuel de la Société Française de Pharmacologie et de Thérapeutique en 2008. Elles...

Cite
Micallef-Roll J, Lapeyre-Mestre M. Second Meeting of the French CEIP (Centres d'Évaluation et d'Information sur la Pharmacodépendance). Part I: How to Evaluate and Prevent the Abuse and Dependence on Hypnotic/Anxiolytic Drugs?. Therapie. 2009;64(6):355-64doi: 10.2515/therapie/2009054.
Micallef-Roll, J., Lapeyre-Mestre, M. (2009). Second Meeting of the French CEIP (Centres d'Évaluation et d'Information sur la Pharmacodépendance). Part I: How to Evaluate and Prevent the Abuse and Dependence on Hypnotic/Anxiolytic Drugs?. Therapie, 64(6), 355-64. https://doi.org/10.2515/therapie/2009054
Micallef-Roll, Joëlle, et al. "Second Meeting of the French CEIP (Centres d'Évaluation et d'Information sur la Pharmacodépendance). Part I: How to Evaluate and Prevent the Abuse and Dependence on Hypnotic/Anxiolytic Drugs?." Therapie vol. 64,6 (2009): 355-64. doi: https://doi.org/10.2515/therapie/2009054
Micallef-Roll J, Lapeyre-Mestre M. Second Meeting of the French CEIP (Centres d'Évaluation et d'Information sur la Pharmacodépendance). Part I: How to Evaluate and Prevent the Abuse and Dependence on Hypnotic/Anxiolytic Drugs?. Therapie. 2009 Nov-Dec;64(6):355-64. doi: 10.2515/therapie/2009054. PMID: 27392928.
Copy Download .nbib Format: NLM
Warning on increased serious health complications related to non-medical use of nitrous oxide.

Therapie

, Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, Gillet P.
PMID: 32063400
Therapie. 2021 Sep-Oct;76(5):478-479. doi: 10.1016/j.therap.2020.01.002. Epub 2020 Jan 17.

No abstract available.

Cite
, Micallef J, Mallaret M, et al. Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapie. 2020;76(5):478-479doi: 10.1016/j.therap.2020.01.002.
, Micallef, J., Mallaret, M., Lapeyre-Mestre, M., Daveluy, A., Victorri-Vigneau, C., Peyrière, H., Debruyne, D., Deheul, S., Bordet, R., Chevallier, C., Perault-Pochat, M. C., Le Boisselier, R., Libert, F., Chaouachi, L., & Gillet, P. (2021). Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapie, 76(5), 478-479. https://doi.org/10.1016/j.therap.2020.01.002
, et al. "Warning on increased serious health complications related to non-medical use of nitrous oxide." Therapie vol. 76,5 (2021): 478-479. doi: https://doi.org/10.1016/j.therap.2020.01.002
, Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, Gillet P. Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapie. 2021 Sep-Oct;76(5):478-479. doi: 10.1016/j.therap.2020.01.002. Epub 2020 Jan 17. PMID: 32063400.
Copy Download .nbib Format: NLM
Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study.

British journal of haematology

Lafaurie M, Maquet J, Baricault B, Ekstrand C, Christiansen CF, Linder M, Bahmanyar S, Nørgaard M, Sailler L, Lapeyre-Mestre M, Sommet A, Moulis G.
PMID: 34386974
Br J Haematol. 2021 Nov;195(3):456-465. doi: 10.1111/bjh.17709. Epub 2021 Aug 12.

We aimed to assess the risk factors of venous thrombosis (VT) and arterial thrombosis (AT) in adults with primary immune thrombocytopenia (ITP), particularly in relation to treatments. The population comprised all incident primary ITP adults in France between 2009...

Cite
Lafaurie M, Maquet J, Baricault B, et al. Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study. Br J Haematol. 2021;195(3):456-465doi: 10.1111/bjh.17709.
Lafaurie, M., Maquet, J., Baricault, B., Ekstrand, C., Christiansen, C. F., Linder, M., Bahmanyar, S., Nørgaard, M., Sailler, L., Lapeyre-Mestre, M., Sommet, A., & Moulis, G. (2021). Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study. British journal of haematology, 195(3), 456-465. https://doi.org/10.1111/bjh.17709
Lafaurie, Margaux, et al. "Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study." British journal of haematology vol. 195,3 (2021): 456-465. doi: https://doi.org/10.1111/bjh.17709
Lafaurie M, Maquet J, Baricault B, Ekstrand C, Christiansen CF, Linder M, Bahmanyar S, Nørgaard M, Sailler L, Lapeyre-Mestre M, Sommet A, Moulis G. Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study. Br J Haematol. 2021 Nov;195(3):456-465. doi: 10.1111/bjh.17709. Epub 2021 Aug 12. PMID: 34386974.
Copy Download .nbib Format: NLM
Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors.

British journal of clinical pharmacology

Chu TH, Rueter M, Palmaro A, Lapeyre-Mestre M.
PMID: 34327727
Br J Clin Pharmacol. 2021 Jul 29; doi: 10.1111/bcp.15011. Epub 2021 Jul 29.

AIMS: A better knowledge of opioid prescribing patterns would help to identify areas of potential improvement in cancer pain management. This study aimed to identify potential inappropriate use (PIU) of strong opioid analgesics in cancer outpatients in their last...

Cite
Chu TH, Rueter M, Palmaro A, et al. Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors. Br J Clin Pharmacol. 2021;doi: 10.1111/bcp.15011.
Chu, T. H., Rueter, M., Palmaro, A., & Lapeyre-Mestre, M. (2021). Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors. British journal of clinical pharmacology, . https://doi.org/10.1111/bcp.15011
Chu, Thanh Hang, et al. "Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors." British journal of clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/bcp.15011
Chu TH, Rueter M, Palmaro A, Lapeyre-Mestre M. Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors. Br J Clin Pharmacol. 2021 Jul 29; doi: 10.1111/bcp.15011. Epub 2021 Jul 29. PMID: 34327727.
Copy Download .nbib Format: NLM
Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France.

European journal of pain (London, England)

Lavergne J, Debin M, Blanchon T, Colizza V, Dassieu L, Gimenez L, Kengne-Kuetche C, Lapeyre-Mestre M, Dupouy J.
PMID: 34958720
Eur J Pain. 2021 Dec 27; doi: 10.1002/ejp.1901. Epub 2021 Dec 27.

BACKGROUND: In Europe and France, the use of opioid analgesic drugs has become widespread as an option for pain management. However, their use can lead to nonmedical use and/or opioid use disorder (OUD). This work aimed to assess the...

Cite
Lavergne J, Debin M, Blanchon T, et al. Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France. Eur J Pain. 2021;doi: 10.1002/ejp.1901.
Lavergne, J., Debin, M., Blanchon, T., Colizza, V., Dassieu, L., Gimenez, L., Kengne-Kuetche, C., Lapeyre-Mestre, M., & Dupouy, J. (2021). Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France. European journal of pain (London, England), . https://doi.org/10.1002/ejp.1901
Lavergne, Justine, et al. "Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France." European journal of pain (London, England) vol. (2021). doi: https://doi.org/10.1002/ejp.1901
Lavergne J, Debin M, Blanchon T, Colizza V, Dassieu L, Gimenez L, Kengne-Kuetche C, Lapeyre-Mestre M, Dupouy J. Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France. Eur J Pain. 2021 Dec 27; doi: 10.1002/ejp.1901. Epub 2021 Dec 27. PMID: 34958720.
Copy Download .nbib Format: NLM
A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).

Drug safety

Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A.
PMID: 34714529
Drug Saf. 2021 Oct 29; doi: 10.1007/s40264-021-01124-5. Epub 2021 Oct 29.

INTRODUCTION: Analgesics are among the most widely used drugs worldwide. This study describes the population treated with narcotic analgesics, their therapeutic indications and how the data have evolved over a decade.METHODS: A cross-sectional, national, multicentre survey study was conducted...

Cite
Perri-Plandé J, Miremont-Salamé G, Micallef J, et al. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Saf. 2021;doi: 10.1007/s40264-021-01124-5.
Perri-Plandé, J., Miremont-Salamé, G., Micallef, J., Herman, C., Baumevieille, M., Abriat, F., Lapeyre-Mestre, M., Haramburu, F., Daveluy, A. (2021). A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug safety, . https://doi.org/10.1007/s40264-021-01124-5
Perri-Plandé, Joelle, et al. "A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019)." Drug safety vol. (2021). doi: https://doi.org/10.1007/s40264-021-01124-5
Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Saf. 2021 Oct 29; doi: 10.1007/s40264-021-01124-5. Epub 2021 Oct 29. PMID: 34714529.
Copy Download .nbib Format: NLM
Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France.

European journal of pain (London, England)

Lavergne J, Debin M, Blanchon T, Colizza V, Dassieu L, Gimenez L, Kengne-Kuetche C, Lapeyre-Mestre M, Dupouy J.
PMID: 34958720
Eur J Pain. 2021 Dec 27; doi: 10.1002/ejp.1901. Epub 2021 Dec 27.

BACKGROUND: In Europe and France, the use of opioid analgesic drugs has become widespread as an option for pain management. However, their use can lead to nonmedical use and/or opioid use disorder (OUD). This work aimed to assess the...

Cite
Lavergne J, Debin M, Blanchon T, et al. Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France. Eur J Pain. 2021;doi: 10.1002/ejp.1901.
Lavergne, J., Debin, M., Blanchon, T., Colizza, V., Dassieu, L., Gimenez, L., Kengne-Kuetche, C., Lapeyre-Mestre, M., & Dupouy, J. (2021). Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France. European journal of pain (London, England), . https://doi.org/10.1002/ejp.1901
Lavergne, Justine, et al. "Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France." European journal of pain (London, England) vol. (2021). doi: https://doi.org/10.1002/ejp.1901
Lavergne J, Debin M, Blanchon T, Colizza V, Dassieu L, Gimenez L, Kengne-Kuetche C, Lapeyre-Mestre M, Dupouy J. Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France. Eur J Pain. 2021 Dec 27; doi: 10.1002/ejp.1901. Epub 2021 Dec 27. PMID: 34958720.
Copy Download .nbib Format: NLM
Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies.

EClinicalMedicine

Lapeyre-Mestre M.
PMID: 31891147
EClinicalMedicine. 2019 Nov 23;17:100216. doi: 10.1016/j.eclinm.2019.11.009. eCollection 2019 Dec.

No abstract available.

Cite
Lapeyre-Mestre M. Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies. EClinicalMedicine. 2019;17:100216doi: 10.1016/j.eclinm.2019.11.009.
Lapeyre-Mestre, M. (2019). Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies. EClinicalMedicine, 17100216. https://doi.org/10.1016/j.eclinm.2019.11.009
Lapeyre-Mestre, Maryse. "Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies." EClinicalMedicine vol. 17 (2019): 100216. doi: https://doi.org/10.1016/j.eclinm.2019.11.009
Lapeyre-Mestre M. Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies. EClinicalMedicine. 2019 Nov 23;17:100216. doi: 10.1016/j.eclinm.2019.11.009. eCollection 2019 Dec. PMID: 31891147; PMCID: PMC6933181.
Copy Download .nbib Format: NLM
Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives.

Fundamental & clinical pharmacology

Revet A, Moulis G, Raynaud JP, Bui E, Lapeyre-Mestre M.
PMID: 33998708
Fundam Clin Pharmacol. 2021 May 17; doi: 10.1111/fcp.12696. Epub 2021 May 17.

PURPOSE: This systematic review registered in PROSPERO (CRD42021225296) aimed to describe the use of the French national health insurance information system, which covers the entire French population (67 million inhabitants), for research in the field of mental health.METHODS: Three...

Cite
Revet A, Moulis G, Raynaud JP, et al. Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives. Fundam Clin Pharmacol. 2021;doi: 10.1111/fcp.12696.
Revet, A., Moulis, G., Raynaud, J. P., Bui, E., & Lapeyre-Mestre, M. (2021). Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives. Fundamental & clinical pharmacology, . https://doi.org/10.1111/fcp.12696
Revet, Alexis, et al. "Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives." Fundamental & clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/fcp.12696
Revet A, Moulis G, Raynaud JP, Bui E, Lapeyre-Mestre M. Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives. Fundam Clin Pharmacol. 2021 May 17; doi: 10.1111/fcp.12696. Epub 2021 May 17. PMID: 33998708.
Copy Download .nbib Format: NLM
A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).

Drug safety

Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A.
PMID: 34714529
Drug Saf. 2022 Jan;45(1):37-44. doi: 10.1007/s40264-021-01124-5. Epub 2021 Oct 29.

INTRODUCTION: Analgesics are among the most widely used drugs worldwide. This study describes the population treated with narcotic analgesics, their therapeutic indications and how the data have evolved over a decade.METHODS: A cross-sectional, national, multicentre survey study was conducted...

Cite
Perri-Plandé J, Miremont-Salamé G, Micallef J, et al. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Saf. 2021;45(1):37-44doi: 10.1007/s40264-021-01124-5.
Perri-Plandé, J., Miremont-Salamé, G., Micallef, J., Herman, C., Baumevieille, M., Abriat, F., Lapeyre-Mestre, M., Haramburu, F., Daveluy, A. (2022). A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug safety, 45(1), 37-44. https://doi.org/10.1007/s40264-021-01124-5
Perri-Plandé, Joelle, et al. "A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019)." Drug safety vol. 45,1 (2022): 37-44. doi: https://doi.org/10.1007/s40264-021-01124-5
Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Saf. 2022 Jan;45(1):37-44. doi: 10.1007/s40264-021-01124-5. Epub 2021 Oct 29. PMID: 34714529.
Copy Download .nbib Format: NLM
Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study".

Movement disorders : official journal of the Movement Disorder Society

Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, Montastruc JL.
PMID: 32056308
Mov Disord. 2020 Feb;35(2):376-377. doi: 10.1002/mds.27956.

No abstract available.

Cite
Pacheco-Paez T, Montastruc F, Rousseau V, et al. Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study". Mov Disord. 2020;35(2):376-377doi: 10.1002/mds.27956.
Pacheco-Paez, T., Montastruc, F., Rousseau, V., Chebane, L., Lapeyre-Mestre, M., Renoux, C., & Montastruc, J. L. (2020). Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study". Movement disorders : official journal of the Movement Disorder Society, 35(2), 376-377. https://doi.org/10.1002/mds.27956
Pacheco-Paez, Tatiana, et al. "Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study"." Movement disorders : official journal of the Movement Disorder Society vol. 35,2 (2020): 376-377. doi: https://doi.org/10.1002/mds.27956
Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, Montastruc JL. Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study". Mov Disord. 2020 Feb;35(2):376-377. doi: 10.1002/mds.27956. PMID: 32056308.
Copy Download .nbib Format: NLM
A comparative survey of antidepressant drug prescribing habits of general practitioners and psychiatrists.

Clinical drug investigation

Lapeyre-Mestre M, Desboeuf K, Aptel I, Chale JJ, Montastruc JL.
PMID: 18370518
Clin Drug Investig. 1998;16(1):53-61. doi: 10.2165/00044011-199816010-00007.

OBJECTIVE: Clinical experience suggests important differences in prescriptions from general practitioners and specialists. This study investigated these differences and their determinants for antidepressant drug prescribing intentions by general practitioners and psychiatrists in France.STUDY PARTICIPANTS: In May 1995, a mail...

Cite
Lapeyre-Mestre M, Desboeuf K, Aptel I, et al. A comparative survey of antidepressant drug prescribing habits of general practitioners and psychiatrists. Clin Drug Investig. 1998;16(1):53-61doi: 10.2165/00044011-199816010-00007.
Lapeyre-Mestre, M., Desboeuf, K., Aptel, I., Chale, J. J., & Montastruc, J. L. (1998). A comparative survey of antidepressant drug prescribing habits of general practitioners and psychiatrists. Clinical drug investigation, 16(1), 53-61. https://doi.org/10.2165/00044011-199816010-00007
Lapeyre-Mestre, M, et al. "A comparative survey of antidepressant drug prescribing habits of general practitioners and psychiatrists." Clinical drug investigation vol. 16,1 (1998): 53-61. doi: https://doi.org/10.2165/00044011-199816010-00007
Lapeyre-Mestre M, Desboeuf K, Aptel I, Chale JJ, Montastruc JL. A comparative survey of antidepressant drug prescribing habits of general practitioners and psychiatrists. Clin Drug Investig. 1998;16(1):53-61. doi: 10.2165/00044011-199816010-00007. PMID: 18370518.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 40 entries